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Summary
Background: Pembrolizumab immunotherapy has been associated with hepatotoxic‐
ity in 1%‐10% of oncology patients treated in clinical trials.
Aim: To describe the incidence, phenotypes and outcomes of liver injury in a large 
cohort of solid organ tumour patients receiving pembrolizumab
Methods: Liver injury was defined by serum alanine aminotransferase, alkaline phos‐
phatase, and/or total bilirubin levels exceeding threshold values. The likelihood of 
drug‐induced liver injury was adjudicated by expert opinion.
Results: Seventy (14.3%) of the 491 pembrolizumab‐treated patients developed liver 
injury at a median of 62 days (6‐478) and 71.4% had a cholestatic injury profile at 
onset. The median age, gender and tumour types of liver injury patients were similar 
to those without, but hepatic metastases (53% vs 21%, P < 0.01) and prior systemic 
and liver‐directed therapy (71% vs 53%, P < 0.01) were more commonly observed in 
liver injury patients. During follow‐up, liver injury patients were less likely to experi‐
ence tumour remission (10% vs 40.4%) and had higher mortality (67.1% vs 33.7%). 
Only 20 (28.6%) liver injury cases were adjudicated as probable drug‐induced hepa‐
totoxicity; these patients were significantly more likely to present with an hepatocel‐
lular/mixed injury pattern (65% vs 12%), to receive corticosteroids (55% vs 12%) and 
had lower mortality (45% vs 76%) during follow‐up.
Conclusions: Oncology patients treated with pembrolizumab who develop liver in‐
jury experience poorer outcomes during follow‐up. The low incidence of confirmed 
drug hepatotoxicity highlights the need for thorough medical evaluation before initi‐
ating corticosteroids to optimise patient care.
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1  | INTRODUC TION
Treatment of advanced solid organs tumours has rapidly evolved in 
the past 10 years with the approval of over 60 new agents.1 Immune 
checkpoint inhibitors (ICI) that target the cell surface receptors of 
the programmed‐death receptor ligand‐1 (PD‐1) and CTLA‐4 invoke 
a regulated T‐cell response against tumour cells by inhibiting internal 
T‐cell checkpoints.2‐5 In addition to improved tumour responses, use 
of these monoclonal antibodies has been associated with a systemic 
form of drug toxicity that has prominent autoimmune features com‐
monly referred to as immune‐related adverse events (irAE’s) which 
can afflict many internal organs,6‐8 including the liver in 1%‐10% of 
patients treated in clinical trials.2,9,10 Although the definitions used 
to determine the incidence and severity of hepatotoxicity have been 
variable, most studies have demonstrated a higher incidence of liver 
injury in patients treated with high dose anti‐CTLA‐4 agents and 
with combination regimens of anti‐CTLA‐4 and anti‐PD1/ anti‐PDL1 
therapy. But the incidence, phenotype and risk factors for liver in‐
jury in patients receiving these drugs in clinical practice are not well 
described.
Pembrolizumab is an ICI administered as an intravenous infusion 
every 3 weeks that was initially approved for patients with advanced 
melanoma in 2014.11 Pembrolizumab is most commonly used in late‐
stage cancer patients who likely harbour known or occult metasta‐
ses. Oncology practice guidelines recommend that corticosteroids 
and other immunosuppressants be rapidly initiated in any patient 
receiving an ICI with an ALT ≥ 3x upper limit of normal (ULN).9 
However, the aetiology of these liver biochemistry abnormalities 
and the impact of developing liver injury on clinical outcomes are not 
well described. The aim of this study is to determine the incidence, 
aetiologies and outcomes of consecutive cancer patients with vary‐
ing tumour types who developed liver injury during pembrolizumab 
immunotherapy at a large tertiary care cancer centre.
2  | MATERIAL S AND METHODS
2.1 | Data collection
This retrospective study was approved by the Institutional Review 
Board of Michigan Medicine. Consecutive patients receiving pem‐
brolizumab immunotherapy between 1 January 2014 and 1 January 
2018 were identified from the Michigan Medicine Cancer Registry 
database. One patient was excluded due to enrolment in a double‐
blind clinical trial yielding a total of 491 evaluable patients. Using 
Data Direct, a self‐serve electronic medical record (EMR) search 
tool, patient health data were extracted including birthdate, sex, 
race, ethnicity, body mass index (BMI) and the dose and frequency 
of pembrolizumab infusions administered. In addition, serial serum 
aspartate aminotransferase (AST), alanine aminotransferase (ALT), 
alkaline phosphatase (ALP), total bilirubin and international nor‐
malised ratio (INR) levels prior to, during, and after immunotherapy 
were reviewed. Available diagnostic test results in patients with liver 
injury including serum antinuclear antibody (ANA), smooth muscle 
antibody (SMA), hepatitis A, B and C serologies and results of liver 
imaging were extracted. All pembrolizumab doses were verified 
through chart review. Manual EMR review was used to record ad‐
ditional data including prior treatment with other immunotherapy or 
liver‐directed therapy within the prior year, tumour type, pre‐treat‐
ment liver imaging, liver biopsy reports, management of adverse 
events including use of steroids, tumour response and date and 
cause of death.
2.2 | Definition of liver injury and 
adjudication of aetiology
Baseline liver biochemistries of serum AST, ALT, ALP and total bili‐
rubin were defined as those results obtained immediately prior to 
the first pembrolizumab dose. Liver injury on treatment was defined 
using the Drug‐Induced Liver Injury Network (DILIN) study criteria12 
as any of the following within 90 days of the last pembrolizumab 
infusion:
1. Serum ALT ≥ 5x upper limit of normal (or baseline if 
baseline > ULN)
2. Serum ALP ≥ 2x ULN (or baseline if baseline > ULN)
3. Total bilirubin ≥ 2.5 mg/dL (or > 2x baseline if baseline > ULN)
The peak liver biochemistry test results were recorded as the maxi‐
mum values after meeting liver injury criteria; normalisation of liver 
biochemistries was determined when the abnormal lab test returned 
to less than ULN. Four physician reviewers (IT, RD, RJF, AYK) adjudi‐
cated each liver injury case to determine the likelihood of drug‐induced 
hepatotoxicity versus an alternative aetiology and assigned each case 
an expert opinion DILIN causality score ranging from 1 = definite, 
2 = highly likely, 3 = probable, 4 = possible, and 5 = Unlikely.12 In addi‐
tion, R values were calculated using the equation R = (serum ALT/ULN)/ 
(ALP/ULN) and classified as hepatocellular (R > 5), mixed (R = 2‐5), or 
cholestatic (R < 2). The Roussel Uclaf Causality Assessment Method 
(RUCAM)13 was calculated for each of the liver injury cases and com‐
pared with the expert opinion adjudication score. Total RUCAM scores 
vary from –9 to + 14 and are categorised as ≤ 0 = drug excluded as a 
cause; 1 to 2 = unlikely; 3 to 5 = possible; 6 to 8 = probably; >8 = highly 
probable.
2.3 | Statistical analysis
Descriptive statistics were calculated using mean (standard devia‐
tion) or median (range) for normally and nonnormally distributed 
data, respectively. Kaplan‐Meier survival curves were calculated 
from the time of pembrolizumab infusion to death or last available 
follow‐up in patients with and without liver injury. Baseline features 
associated with new onset liver injury were determined using uni‐
variate and multivariate models. Statistical analyses were performed 
using the Chi‐squared, Mann‐Whitney U, and Kruskal‐Wallis tests. 
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Statistical significance was defined as P < 0.05. Analyses were com‐
pleted in RStudio statistical software (Boston, MA).
3  | RESULTS
3.1 | Patient characteristics
A total of 491 patients received pembrolizumab treatment between 
January 2014 and January 2018. During a median follow‐up of 
211 days, 70 (14%) patients met the predefined laboratory criteria for 
liver injury (Figure 1). The liver injury was predominantly cholestatic 
(71.4%) at onset with only 17.1% having a total bilirubin > 2.5 mg/dL. 
The specific lab criteria that were met included serum AST or ALT 
elevations in 12 (17.1%), ALP elevations in 42 (60%), total bilirubin 
elevations in eight (11.4%), ALP and ALT elevations in four (5.7%), 
ALP and total bilirubin in two (2.8%), and all three criteria in two 
(2.8%). Most of the liver injury cases (61%) occurred within the first 
3 months of treatment and 77% occurred within the first 6 months 
of treatment. The median number of pembrolizumab infusions re‐
ceived in those with and without liver injury was significantly lower 
(3 vs 5, P < 0.01). The proportion of pembrolizumab‐treated patients 
who developed liver injury did not substantially change over time 
(data not shown).
The median age, race and BMI of the 70 patients with liver in‐
jury were similar to the 421 without liver injury (Table 1). The types 
and stage of solid organ tumours were also similar in the two groups 
with 65% of the cohort having either metastatic melanoma, lung or 
urothelial cancer. However, the patients with liver injury were sig‐
nificantly more likely to have received prior chemotherapy or liver‐
directed locoregional therapy in the year prior to pembrolizumab 
(71.3% vs 53%, P < 0.01) and to have known hepatic metastases prior 
to treatment (52.9% vs 21.4%, P < 0.001). Interestingly, the presence 
of hepatic steatosis on imaging and the pre‐treatment serum ALT 
and total bilirubin levels were similar in patients with and without 
liver injury but the pre‐treatment serum AST and ALP levels were 
both significantly higher in the liver injury group. During follow‐up, a 
significantly lower rate of tumour remission (10% vs 40.4%) was ob‐
served in those with liver injury as well as a significantly lower actu‐
arial patient survival (33.7% vs 67.1%) compared to the 421 patients 
without liver injury (Figure 2). Finally, the frequency of nonhepatic 
irAE was similar in those with and without liver injury (15% vs 21%) 
suggesting that the risk of developing liver injury was independent 
of other adverse events.
F I G U R E  1   Patient population and 
flowchart. There were 491 patients who 
received pembrolizumab treatment for 
cancer. During treatment, 70 patients met 
laboratory criteria for liver injury while the 
remaining 421 patients did not. Following 
expert opinion adjudication, only 20 (28%) 
of the liver injury cases were attributed to 
a medication
N = 491 Pembrolizumab 
treated patients
(1/14-1/18)
N = 70 
Liver injury
N = 421 
No liver injury
N = 20 
Definite/highlylikely/probable DILI 
(DILIN score 1-3)
N = 50 
Possible/ Unlikely DILI
(DILIN score 4-5)
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3.2 | Factors associated with development of 
liver injury
Variables which demonstrated a P value of <0.10 (Table 1) were 
entered into univariate and multivariate logistic regression models 
of new onset liver injury. After adjusting for subject gender, pre‐
treatment AST and ALP, and prior liver‐directed therapy, only the 
presence of hepatic metastases was an independent predictor of 
liver injury (Odds ratio: 3.58, 95% CI: 2.03‐6.31, P < 0.01). (Table S1).
3.3 | Expert adjudication of the 70 liver injury cases
All of the available laboratory, radiological and clinical data of the 70 
patients with liver injury were reviewed and scored by the investigators 




N = 421 P value
Age (y) 64 [16‐89] 65 [16‐97] 0.71
Male 52 (74.3) 267 (63.4) 0.08
BMI (kg/m2) 28.4 [14.6‐44.7] 27.2 [14.8‐49.7] 0.57
Race
Caucasian 63 (90.0) 399 (94.8) 0.12
African American 3 (4.3) 10 (2.4)
Asian 2 (2.9) 3 (0.7)
Native Hawaiian/Other Pacific 0 (0.0) 2 (0.5)
American Indian or Alaska Native 0 (0.0) 1 (0.2)
Unknown 2 (2.9) 6 (1.4)
Ethnicity
Non‐Hispanic/Latino 67 (95.7) 409 (97.1) 0.52
Hispanic/Latino 3 (4.3) 4 (1.0)
Unknown 0 (0.0) 8 (1.9)
Prior immunotherapy (ipilimumab, nivolumab) 11 (15.7) 67 (15.8) 0.97
Total # pembrolizumab infusions 3 [1‐20] 5 [1‐43] 0.01
Duration of follow‐up (d) 142.4 [2.3‐1146.3] 230.4 (2.4‐1159.4] 0.12
Cancer type
Melanoma 30 (42.9) 182 (43.2) 0.95
Lung 5 (7.1) 60 (14.3)
Urothelial 11 (15.7) 35 (8.2)
Other 24 (34.3) 144 (34.2)
Baseline Hepatic metastases 37 (52.9) 90 (21.4) <0.01
Prior chemotherapy, XRT, TACE, radioembolisation 50 (71.3) 223 (53.0) <0.01
Baseline Hepatic Steatosis 16 (22.9) 89 (21.1) 0.75
Other nonhepatic irAE’s 11 (15.7) 87 (20.7) 0.34
Pre‐treatment labs
AST (IU/L) 28 [12‐213] 24 [11‐179] 0.02
ALT (IU/L) 22 [8‐83] 21 [8‐173] 0.72
Alkaline phosphatase (IU/L) 108 [43‐523] 90 [26‐1147] <0.01
Total bilirubin (IU/L) 0.5 [0.1‐1.1] 0.4 [0.1‐8.3] 0.72
Tumour outcome through 1/1/18 <0.01
Progression 16 (22.9) 109 (25.9)
Stable/ remission 7 (10) 170 (40.4)
Death 47 (67.1) 142 (33.7)
Note: Data presented as median [range] or n (%).
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; irAE, immune‐related adverse event; TACE, 
transarterial chemoembolisation; XRT, radiotherapy.
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using the DILIN expert opinion scale of 1 (definite) to 5 (unlikely).12 
There were one definite, six highly likely and 13 probable drug‐induced 
hepatotoxicity cases while the remaining 50 cases were adjudicated 
as possible (21) or unlikely (29) cases of drug hepatotoxicity (Table 2). 
The 20 (28.6%) patients with a causality score of 1, 2 or 3 represented 
4.1% of all of the 491 patients treated with pembrolizumab. However, 
three of these high causality cases were attributed to a drug other than 
pembrolizumab (ipilimumab, vemurafenib and dabrafenib) but were 
analysed with the pembrolizumab hepatotoxicity cases.
The median number of pembrolizumab infusions prior to liver 
injury onset was similar in the high and low causality cases (3 vs 3, 
P = 0.63), and the time to liver injury onset was also similar (66 vs 
62 days, P = 0.56). In addition, the baseline patient demographic fea‐
tures and pre‐treatment liver biochemistries were similar in the high 
versus low causality liver injury cases. However, the 20 patients with 
high causality scores were more likely to have an acute hepatocellular 
or mixed liver injury at onset compared to the 50 low causality patients 
(65% vs 12%, P < 0.01). In addition, the high causality cases had signifi‐
cantly higher peak serum ALT levels but the proportion with jaundice 
was similar (Table 2). The most commonly identified alternative cause 
of liver injury among the 50 possible/unlikely cases was progressive 
hepatic tumour metastases (56%), while other aetiologies included 
malignant biliary obstruction (4%), nonhepatic disease (9%) and other 
biliary obstruction or unknown (2%).
3.4 | RUCAM scoring of the 70 liver injury cases
The RUCAM scores were significantly higher in the 20 high causal‐
ity cases compared to the low causality cases (5 vs 2). The overall 
level of concordance between the RUCAM and DILIN expert opinion 
scales was relatively good with a Pearson correlation coefficient of 
−0.57 (Figure S1).
3.5 | Clinical outcomes in the 70 patients with 
liver injury
The median duration of follow‐up in the low causality cases was 
significantly shorter (122 vs 333 days, P < 0.01) largely due to the 
higher observed mortality during follow‐up in the low causality 
cases (76% vs 45%, P = 0.01) (Figure 3). The adjudicated causes of 
death were tumour progression in seven of the nine high causal‐
ity patients who died and tumour progression in 31 of the 38 low 
causality patients who died. None of the nine deaths in the high 
causality group were directly attributed to pembrolizumab drug 
hepatotoxicity. The higher mortality in the low causality group 
may have, in part, been due to the higher incidence of hepatic 
metastases on pre‐treatment imaging (66% vs 20%) as well as the 
lower rate of objective tumour stabilisation/remission during fol‐
low‐up (4% vs 25%).
The high causality patients were significantly more likely to 
receive corticosteroids after liver injury onset (Table 2). They also 
experienced more frequent normalisation of liver biochemistry ab‐
normalities during follow‐up. Of note, none of the high causality 
case patients were re‐challenged with pembrolizumab. A review of 
the available liver pathology in four of the high causality patients 
who underwent biopsy at a median of 14 days after liver injury onset 
demonstrated a variety of histological findings (Table S2). However, 
none of these patients had eosinophils, granulomas or plasma cells 
noted on biopsy nor detectable serum autoantibodies.
3.6 | Analysis of 70 liver injury cases stratified by 
liver injury pattern
The 70 liver injury cases were stratified by the biochemical pat‐
tern of liver injury at onset (ie hepatocellular, cholestatic, mixed) 
as defined by the R ratio (Table S3). There were 11 patients who 
presented with an acute hepatocellular injury profile, 51 with a 
cholestatic profile, and eight with a mixed profile. Variables with 
significant differences between groups are similar to the results 
obtained when stratifying the 70 liver injury patients by DILIN 
expert opinion score. There were significant differences in the 
frequency of baseline hepatic metastases, hepatic steatosis and 
pre‐treatment serum AST and ALT levels. In addition, those with 
an acute hepatocellular or mixed injury were more likely to re‐
ceive corticosteroids and normalise their liver biochemical abnor‐
malities during follow‐up. Finally, subjects with a cholestatic liver 
injury profile also had a poorer prognosis during follow‐up than 
those presenting with a hepatocellular or mixed laboratory profile.
4  | DISCUSSION
The onset of liver biochemical abnormalities at 3‐6 months after 
starting treatment is a well recognised side effect of check‐
point inhibitor immunotherapy.2 Grading schemas largely based 
upon the level of serum ALT elevation have been developed 
F I G U R E  2   Actuarial patient survival after starting 
pembrolizumab treatment. The overall patient survival in the 
70 patients who developed liver injury was significantly lower 
compared to the 421 without liver injury during follow‐up 
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n = 50 P value
Age (y) 64.5 [32‐85] 64 [16‐89] 0.93
Male 14 (70) 38 (76) 0.60
BMI (kg/m2) 28.8 [21.1‐39.5] 28.4 [14.6‐44.7] 0.80
Race
Caucasian 19 (95) 44 (88) 0.38
African American 0 (0.0) 3 (6.0)
Asian 0 (0.0) 2 (4.0)
Unknown 1 (5.0) 1 (2.0)
Ethnicity
Non‐Hispanic/Latino 20 (100.0) 47 (94.0) 0.26
Hispanic/Latino 0 (0.0) 3 (6.0)
Unknown 0 (0.0) 0 (0.0)
Prior ipilimumab, nivolumab, or both 5 (25.0) 6 (12.0) 0.18
Total # pembrolizumab infusions 3 [1‐18] 3 [1‐20] 0.72
Duration of follow‐up (d) 333 [54‐1146] 121 [2‐785] <0.01
Cancer type
Melanoma 10 (50.0) 20 (40.0) 0.45
Lung 3 (15.0) 2 (4.0)
Urothelial 2 (10.0) 9 (18.0)
Other 5 (25.0) 19 (38.0)
Baseline Hepatic metastases 4 (20.0) 33 (66.0) <0.01
Prior chemo, XRT, TACE, radioembolisation 11 (55.0) 39 (78.0) 0.05
Baseline hepatic steatosis 5 (25.0) 11 (22.0) 0.79
Pre‐treatment labs
AST (IU/L) 20 [12‐49] 30 [14‐213] 0.01
ALT (IU/L) 20 [8‐59] 23 [9‐83] 0.12
Alkaline phosphatase (IU/L) 83 [43‐220] 124 [55‐523] <0.01
Total bilirubin (IU/L) 0.45 [0.1‐1.1] 0.5 [0.2‐1] 0.92
Other nonhepatic irAE’s 4 (20.0) 7 (14.0)
Referral to hepatology 5 (25.0) 5 (10.0) 0.11
Pembrolizumab start to liver injury (d) 66 [6‐478] 62 [9‐467] 0.56
# infusions prior to liver injury 3 [1‐18] 3 [1‐18] 0.63
Patients with LFT normalisation during follow‐up 13 (65.0) 7 (14.0) <0.01
Time to LFT normalisation (days) 27 [13‐224] 26 [1‐139] 0.72
Peak Liver biochemistries
Alkaline phosphatase (IU/L) 324 [54‐1842] 568.5 [99‐2735] 0.02
ALT (IU/L) 294.5 [10‐674] 101.5 [8‐775] <0.01
AST (IU/L) 188.5 [15‐366] 141.5 [20‐853] 0.86
Total bilirubin (IU/L) 1.1 [0.2‐6.6] 1.6 [0.3‐19.2] 0.28
Patients with total bilirubin > 2.5 5 (25.0) 19 (38.0) 0.30
R ratio at injury onset 2.5 [0.1‐16.0] 0.6 [0.1‐7.5]
Hepatocellular R > 5.0 8 (40.0) 3 (6.0) <0.01
Cholestatic R < 2.0 7 (35.0) 44 (88.0) <0.01
Mixed R = 2.0‐5.0 5 (25.0) 3 (6.0) 0.02
(Continues)
806  |     TSUNG eT al
and incorporated into clinical practice guidelines as well as rec‐
ommendations for the evaluation of other potential causes.14 
However, the risk factors and outcomes in patients who develop 
any form of biochemical liver injury during checkpoint inhibitor 
immunotherapy remain poorly understood. In this study of 491 
consecutive patients receiving pembrolizumab, liver injury oc‐
curred in 70 (14%) patients. In general, liver injury was predomi‐
nantly cholestatic (R ratio < 2.0) and mild in severity at onset and 
the baseline demographic and laboratory features of the patients 
with liver injury versus those without liver injury were similar 
(Table 1). However, patients who experienced liver injury had a 
significantly lower tumour response and a higher mortality during 
follow‐up (Figure 2). The poorer outcomes in the liver injury group 
may relate to the larger proportion with baseline hepatic metas‐
tases and other recent treatments prior to pembrolizumab that is 
consistent with more advanced and refractory cancer. On multi‐
variate analysis, pre‐treatment hepatic metastases were the only 
independent baseline factor associated with the development of 
liver injury (Table S1).
Only a minority of the liver injury cases were attributed to pem‐
brolizumab hepatotoxicity (29%) while cancerous replacement of 
the liver accounted for most of the other patients with benign or 
malignant biliary obstruction identified in 5.7%. (Table 2). These data 
are important since most prior publications on this topic have simply 
described the incidence of liver injury during treatment but not ad‐
judicated the cause.8,15 Furthermore, current treatment guidelines 
recommend the rapid institution of corticosteroids and withholding 
of further treatment whenever the serum ALT exceeds 3x ULN or 
ALP increases to more than 2x ULN.9 However, our data indicate 
that careful clinical assessment of the cause of liver injury is critical 
including contrast enhanced cross‐sectional imaging of the liver to 
assess for tumour progression and to help ensure that the appropri‐
ate actions are undertaken.16 If other prospective studies confirm 
our observations, less frequent use of immunosuppression may be 
indicated and additional cancer treatments could be offered to im‐
prove patient outcomes. In addition, prospectively obtained liver 
biopsies in patients with elevated liver biochemistries may prove 
informative to help guide management. Our data demonstrate that 
patients who present with an acute hepatocellular or mixed injury 
pattern are more likely to be experiencing immune‐mediated liver 
injury due to pembrolizumab but there was no particular serum ALT, 
ALP, or bilirubin level that reliably differentiated patients with DILI 
from other causes of liver injury (Table S3).
The 20 patients with drug hepatotoxicity (DILIN score of 1‐3) 
were more likely to have a hepatocellular or mixed injury at presen‐
tation compared to the 50 with low causality scores (65% vs 12%). In 
addition, these patients had higher peak serum ALT levels and were 
more likely to receive corticosteroids and experience liver biochem‐
istry normalisation during follow‐up suggesting that their liver in‐
jury was indeed immune‐mediated and steroid‐responsive (Table 2). 
Unfortunately, results of serum autoantibodies and quantitative im‐
munoglobulin levels were available in only four of the 20 high causal‐
ity cases. This may be due to the fact that only a small proportion of 
the liver injury patients (14%) were seen by a GI or liver specialist and 
even fewer (7%) underwent a liver biopsy. Interestingly, the 20 high 
F I G U R E  3   Actuarial patient survival in 70 liver injury patients. 
The 20 patients with probable drug‐induced hepatotoxicity (DILIN 
score of 1, 2, 3) had a significantly better survival compared to 
the 50 patients with other causes of liver injury (DILIN score 4, 5) 















0.00 P = 0.00044
Number at risk
DILIN score : 1-2-3
DILIN score : 1-2-3
DILIN score : 4-5















n = 50 P value
RUCAM 5 [1‐9] 2 [0‐9] <0.01
Steroids for liver injury 11 (55.0) 6 (12.0) <0.01
Patients with pembrolizumab discontinued after liver injury 17 (85.0) 39 (78.0) 0.51
Tumour outcome through 1/1/18 < 0.01
Progression 6 (30.0) 10 (20.0)
Stable/Remission 5 (25.0) 2 (4.0)
Death 9 (45.0) 38 (76.0)
Note: Data presented as median [range] or n (%).
Abbreviations: ALT, alanine aminotransferase; AST; aspartate aminotransferase; BMI, body mass index; irAE, immune‐related adverse event; LFT, 
liver function test; RUCAM, Roussel Uclaf Causality Assessment; TACE, transarterial chemoembolisation; XRT, radiotherapy.
TA B L E  2   (Continued)
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causality drug hepatotoxicity patients had significantly better short‐
term survival compared to the 50 patients with other causes of liver 
injury (Figure 3). This is likely due to the fact that the high causality 
cases were more likely to experience an objective tumour response 
while the majority of low causality cases had hepatic metastases that 
progressed during follow‐up. Analysis of our data based upon the R‐
value at liver injury onset showed similar results with hepatocellular 
and mixed injury patients being more likely to have a higher causality 
score, receive corticosteroids and normalise their labs during follow‐
up compared to those with a cholestatic profile (Table S3).
Information regarding the liver histology in patients with im‐
munotherapy hepatotoxicity is not well described. Kleiner et al 
originally described 10 patients with moderately severe acute he‐
patocellular injury wherein many had pericentral necrosis or plasma 
cell‐mediated hepatitis.17 In a more recent multicentre French study, 
fibrin ring granulomas, hepatic steatosis and periportal hepatitis 
were more commonly identified than plasma cell hepatitis partic‐
ularly in patients receiving anti‐CTLA‐4 therapy.18 In the current 
study, four high causality patients underwent a liver biopsy at a me‐
dian of 13 days (range 1‐45) after DILI onset but only mild apopto‐
sis and hepatic steatosis were observed (Table S2). Therefore, our 
data are consistent prior reports demonstrating a spectrum of liver 
histopathological abnormalities in patients with pembrolizumab 
hepatotoxicity.19 Whether the pattern or severity of liver pathology 
findings correlates with response to corticosteroids or has indepen‐
dent prognostic value requires further study in a larger number of 
patients undergoing biopsy.
Since expert opinion is not widely available, standardised 
RUCAM scores were also calculated for each of the 70 cases. 
Contrary to our expectations, there was a high degree of concor‐
dance between the RUCAM and expert opinion causality scores 
(Figure S1).20 Interestingly, very few of the cases achieved a very 
high RUCAM score (> 8) (8 cases) since most patients did not un‐
dergo testing for competing causes of liver injury.
Strengths of our study include the large number of patients 
(ie 491) who received pembrolizumab treatment at a single cen‐
tre over a 4‐year period. Furthermore, these therapies were given 
by a limited number of oncologists in a standardised manner. In 
general, the dose of pembrolizumab was 2 mg/kg or 200 mg flat 
dose given every 3 weeks with laboratory monitoring obtained 
prior to each infusion. However, the criteria to withhold an infu‐
sion of pembrolizumab due to hepatotoxicity and when and how 
much corticosteroids to use were variable. Additionally, our EMR 
database did not allow us to determine the cumulative corticoste‐
roid dose administered. However, all of the liver injury cases were 
vetted for causality using an established expert opinion method as 
well as the RUCAM. The high degree of concordance in these two 
scales suggests that the causality assessment used in this study 
was robust and reproducible. A final limitation of our study was 
its retrospective nature and the lack of diagnostic serologies for 
competing causes of liver injury in many of the liver injury cases. 
However, nearly 80% of the patients did undergo contrast en‐
hanced liver imaging after liver injury onset. Going forward, future 
prospective studies should include a more comprehensive assess‐
ment for competing aetiologies of liver injury in patients receiving 
checkpoint inhibitors with hepatotoxicity. However, the value of 
routine assessment of baseline and on treatment autoantibodies 
remains controversial since prior studies have demonstrated a low 
incidence of discriminating high titre autoantibodies in patients 
with bonafide hepatotoxicity.2,17,21
In conclusion, the overall incidence of liver injury observed in 
our study of 14% is somewhat higher than that reported in licens‐
ing trials and other series.2,22 However, the liver injury patients 
had a significantly poorer short‐term survival (Figure 2). Since the 
majority of deaths observed was not due to drug‐induced hepato‐
toxicity, our data suggest that the poorer prognosis is likely due to 
the presence of more advanced cancer and liver metastases prior 
to treatment rather than hepatotoxicity per se from pembrolizumab 
therapy. (Figure 3). Going forward, pembrolizumab‐treated patients 
who develop liver biochemical abnormalities should undergo thor‐
ough evaluation for competing causes of liver injury and liver biopsy, 
whenever feasible, to assist with diagnosis and guide the appropriate 
use of immunosuppressive therapy rather than empiric therapy in all 
patients.
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